Crossmark

AHSA1 as a prognostic biomarker and potential immunotherapeutic target in HNSCC: integrative bulk RNA-seq, scRNA-seq analyses and experimental validation

Crossref DOI link: https://doi.org/10.1186/s12885-025-14833-2

Published Online: 2025-10-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gu, Feihan

Wu, Erli

Yan, Xiaorong

Huang, Wenkai

Chen, Siyuan

Bao, Weimin

Xu, Wenhua

Wang, Yuanyin

Chen, Ran
Funding

Funding for this research was provided by:

Health Research Program of Anhui (AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131, AHWJ2023BAa20131)

Research Fund of Anhui Institute of translational medicine (2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86, 2022zhyx-C86)
License Information

Text and Data Mining valid from 2025-10-14

Version of Record valid from 2025-10-14
More Information

Article History

Received: 19 May 2025

Accepted: 8 August 2025

First Online: 14 October 2025

Declarations

:

: This study was approved by The Ethics Committee of Anhui Medical University’s Affiliated Stomatological Hospital in accordance with the Declaration of Helsinki. The patients/participants provided their written informed consent to participate in this study. The animal study was approved by The Medical Research Ethics Committee of the Anhui Medical University. The study was conducted in accordance with the local legislation and institutional requirements.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below